VX-770, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, was well-tolerated when dosed orally as 150mg or 250mg twice daily for 28 days. In this analysis, no
RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, the company believes that RDEA806
Mr Clyde replaces Mark Casner, who resigned as president, CEO and director of the company to pursue new business opportunities. Mr Clyde has been CFO since November 2002
Following the recommendation for regulatory approval under the European decentralized procedure, Toctino has received national regulatory approval in France. Basilea will submit a pricing and reimbursement dossier to
The acquisition will be financed from the group’s financial resources. Novartis will acquire research, development and manufacturing assets of Nektar’s pulmonary business unit, including tangible assets as well
S Bio will utilize the proceeds to primarily fund the development efforts of its two lead compounds, SB939, a HDAC inhibitor, and SB1518, a JAK 2 inhibitor, both
Breeze 1, the first Phase III clinical trial, was initiated in September 2008. Breeze 2 differs from Breeze 1 in its treatment duration, which will be three months
This R&D expansion in China will allow the rapid growth of clinical programs and aims to encompass all activities, from drug-target identification to late-stage clinical studies, the company
Abbott is evaluating the FDA complete response letter. The company said that it will discuss the letter with the FDA and will provide an update when appropriate. Abbott
Net income for the third quarter of 2008 was $2.08 billion, an increase of 32%, compared to $1.57 billion in the third quarter of 2007. Basic earnings per
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.